Short Interest in NextPlat Corp. (NASDAQ:NXPL) Increases By 34.2%
by Jessica Moore · The Cerbat GemNextPlat Corp. (NASDAQ:NXPL – Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totaling 196,412 shares, an increase of 34.2% from the December 31st total of 146,349 shares. Currently, 1.3% of the company’s shares are short sold. Based on an average daily volume of 84,362 shares, the days-to-cover ratio is currently 2.3 days. Based on an average daily volume of 84,362 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.3% of the company’s shares are short sold.
Institutional Investors Weigh In On NextPlat
A hedge fund recently bought a new stake in NextPlat stock. Simplicity Wealth LLC bought a new position in NextPlat Corp. (NASDAQ:NXPL – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 600,000 shares of the company’s stock, valued at approximately $497,000. Simplicity Wealth LLC owned approximately 2.31% of NextPlat at the end of the most recent reporting period. 1.30% of the stock is owned by hedge funds and other institutional investors.
NextPlat Stock Down 0.9%
NXPL stock traded down $0.01 during midday trading on Monday, reaching $0.67. 23,798 shares of the company’s stock traded hands, compared to its average volume of 56,357. The company has a quick ratio of 2.80, a current ratio of 3.56 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average price is $0.64 and its 200-day moving average price is $0.72. NextPlat has a 52 week low of $0.43 and a 52 week high of $1.12. The company has a market cap of $17.50 million, a price-to-earnings ratio of -2.22 and a beta of 1.23.
NextPlat (NASDAQ:NXPL – Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.08) EPS for the quarter. The business had revenue of $13.75 million for the quarter. NextPlat had a negative return on equity of 34.22% and a negative net margin of 14.58%.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextPlat in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Read Our Latest Research Report on NextPlat
About NextPlat
NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.